The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

GLOW Stack

GLOW Peptide Stack · Wolverine + GHK-Cu

C
Animal replicated
RouteInjectableGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
BPC-157 + TB-500 + GHK-Cu — Recovery and Skin/Connective-Tissue Peptide Stack — Peptide Stack, Recovery Stack, Skin/Connective-Tissue Support.
Why people use it
Used primarily for tissue repair and healing and skin, hair, and cosmetic use.
What the evidence supports
No published human RCT exists for the GLOW Stack as a combination. Human evidence on the card should be read as component-level context only: topical GHK-Cu has human cosmetic studies, while the injectable stack protocol remains extrapolated from component mechanisms and community use.
If you only read one thing

The GLOW Stack adds GHK-Cu's copper-mediated collagen remodeling to the Wolverine healing foundation — a mechanistically logical addition that addresses what Wolverine doesn't: ECM organization and cosmetic tissue quality. The tension: adding GHK-Cu adds the injectable copper safety considerations (active malignancy hard stop, Wilson disease contraindication, copper accumulation risk on long cycles) to the stack's risk profile. The active malignancy hard stop for GHK-Cu applies to the entire GLOW Stack — the other two components have a 'caution' signal for malignancy, but GHK-Cu elevates the whole stack to a hard stop. Additionally, the blended vial format (50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500) fixes the 5:1:1 ratio regardless of individual dosing preferences — understanding when this ratio is appropriate and when separate vials are better is the practical core of this chapter.

Route / form

Same compound, route-specific context. Switch forms instead of opening separate pages.

Evidence fit
Route-specific

Use the route notes below to match form, goal, and evidence quality.

Route caveat
Protocol not standardized

No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.

Protocol anchor
Full dosing section

Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.

Typical dose snapshot
See route notes
Evidence varies by use case
Published literature
0human trials0human studies0animal0in vitro
Evidence reality check
Human evidence
No human studies
0 observational; RCT evidence not present in corpus.
Preclinical base
0 lab signals
0 animal; 0 in-vitro/mechanistic.
Evidence snapshot
No published human RCT exists for the GLOW Stack as a combination. Human evidence on the card should be read as component-level context only: topical GHK-Cu has human cosmetic studies, while the injectable stack protocol remains extrapolated from component mechanisms and community use.
From the chapter quick-reference block.
Properties
Active malignancy: hard stopInjectable: extrapolated
Evidence
CAnimal replicated
Stack Type
Community healing and cosmetic combination. Not FDA-approved. Research chemical combination protocol. Type: stack. Slug: glow-stack. stackGrade: C. Component slugs: ghk-cu-injectable, bpc-157, tb-500. Related stacks: wolverine-stack (subset), klow-stack (extension), fountain-of-youth-stack (shares GHK-Cu).
Stack Indication
Full-spectrum tissue repair and skin rejuvenation: healing (musculoskeletal, connective tissue, post-surgical) + cosmetic/anti-aging (collagen remodeling, skin quality, wound healing at skin level). The GLOW Stack adds the cosmetic and deeper collagen layer to the Wolverine Stack's healing profile.
The Three Components
GHK-Cu (injectable): copper tripeptide; collagen/elastin remodeling, MMP/TIMP balance, gene expression (>1,500 genes), systemic healing enhancement. Evidence: Grade C (animal systemic); zero human RCTs for injectable route. | BPC-157: local angiogenesis, growth factor signaling, gut protection; 35 preclinical studies. | TB-500: systemic cell migration, actin regulation, progenitor cell mobilization. Together: local signal (BPC-157) + systemic cells (TB-500) + collagen matrix remodeling (GHK-Cu).
Standard Blended Vial
70 mg total per vial: 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 (5:1:1 ratio). Reconstitute with 3 mL bacteriostatic water. The reconstituted solution turns blue — this is expected and identifies the copper complex (GHK-Cu). Blue tint = correct composition, not degradation.
The Dual Timeline
BPC-157 and TB-500: healing and anti-inflammatory effects often noticeable within 1-3 weeks. GHK-Cu: collagen remodeling and cosmetic effects develop over 4-8 weeks, with full benefit at 8-12 weeks of consistent use. Running only a 4-week cycle may provide the healing benefit without the full GHK-Cu cosmetic effect. Minimum 8 weeks recommended to capture both timelines.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Check interactions